Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COV006 Phase II study of ChAdOx1 nCoV-19 vaccine in children
ISRCTN15638344Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Feb 2021
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
01
Overview
Phase 2, randomised trial of ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by University of Oxford. Primary endpoints: Local reactogenicity and tolerability, Systemic reactogenicity and tolerability and 3 more. Started Feb 2021; status: completed.
02
Drugs
ChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN15638344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15638344.